Genetic characterization by amplified fragment length polymorphism (AFLP) markers and morphochemical traits of Carica papaya L. genotypes

Carica papaya L. is a native fruit from Central America and Mexico and it is an economically important fruit. As a pre-breeding genetic study, the variability of both parents (L7 and M22) and the F1 individuals derived from their crosses (L7 × M22), was evaluated in terms of 32 morphochemical traits, and contrasted with their genetic diversity indicated by amplified fragment length polymorphism (AFLP) markers. According to morphochemical traits, L7 and M22 were grouped in two different clades. The first group included L7 and 13 genotypes from the F1, while a second group included the parent M22 and 15 other genotypes from the F1 progeny. The analysis based on morphochemical traits showed an average correlation of 0.652 among genotypes. For AFLP analysis the combination of the primers E-ACA/M-CTA had the best polymorphic index (72.73%). When they were grouped based on AFLPs markers, it was confirmed that both parents are genetically distant, and they were again grouped in two different clades. Five genotypes from the F1 population were grouped in the same clade as L7 and shared 55% similarity. Twenty six genotypes were grouped in the same clade as M22, showing 63.3% similarity. Another 12 genotypes (mainly female genotypes) were grouped in a third independent clade. This relative general agreement between the grouping based on a large number of morphochemical traits (including both plant and fruit traits) and that based on its genetic diversity using AFLPs, suggests that morphochemical characterization, together with genetic analysis by AFLPs, can be complementary and useful techniques for the identification and assessment of genetic diversity within C. papaya L. genotypes, that should be useful for genetic breeding programs of this important species.Key words: Morphological markers, AFLP markers, genetic similarity, Carica papaya L

Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy:Study protocol of a cluster randomized clinical trial (Multi-PAP project)

This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD12/0001/0012, RD16/0001/0005), and the European Regional Development Fund ("A way to build Europe").Background: Multimorbidity is associated with negative effects both on people's health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (≥3 chronic diseases) and polypharmacy (≥5 drugs prescribed in ≥3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799Publisher PDFPeer reviewe

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Comparative cellular analysis of motor cortex in human, marmoset and mouse

The primary motor cortex (M1) is essential for voluntary fine-motor control and is functionally conserved across mammals1. Here, using high-throughput transcriptomic and epigenomic profiling of more than 450,000 single nuclei in humans, marmoset monkeys and mice, we demonstrate a broadly conserved cellular makeup of this region, with similarities that mirror evolutionary distance and are consistent between the transcriptome and epigenome. The core conserved molecular identities of neuronal and non-neuronal cell types allow us to generate a cross-species consensus classification of cell types, and to infer conserved properties of cell types across species. Despite the overall conservation, however, many species-dependent specializations are apparent, including differences in cell-type proportions, gene expression, DNA methylation and chromatin state. Few cell-type marker genes are conserved across species, revealing a short list of candidate genes and regulatory mechanisms that are responsible for conserved features of homologous cell types, such as the GABAergic chandelier cells. This consensus transcriptomic classification allows us to use patch-seq (a combination of whole-cell patch-clamp recordings, RNA sequencing and morphological characterization) to identify corticospinal Betz cells from layer 5 in non-human primates and humans, and to characterize their highly specialized physiology and anatomy. These findings highlight the robust molecular underpinnings of cell-type diversity in M1 across mammals, and point to the genes and regulatory pathways responsible for the functional identity of cell types and their species-specific adaptations

26th Annual Computational Neuroscience Meeting (CNS*2017): Part 3 - Meeting Abstracts - Antwerp, Belgium. 15–20 July 2017

This work was produced as part of the activities of FAPESP Research,\ud Disseminations and Innovation Center for Neuromathematics (grant\ud 2013/07699-0, S. Paulo Research Foundation). NLK is supported by a\ud FAPESP postdoctoral fellowship (grant 2016/03855-5). ACR is partially\ud supported by a CNPq fellowship (grant 306251/2014-0)

Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions

Background and Aim: The circulating recombinant form 02_AG (CRF02_AG) is the predominant clade among the human immunodeficiency virus type-1 (HIV-1) non-Bs with a prevalence of 5.97% (95% Confidence Interval-CI: 5.41–6.57%) across Spain. Our aim was to estimate the levels of regional clustering for CRF02_AG and the spatiotemporal characteristics of the largest CRF02_AG subepidemic in Spain.Methods: We studied 396 CRF02_AG sequences obtained from HIV-1 diagnosed patients during 2000–2014 from 10 autonomous communities of Spain. Phylogenetic analysis was performed on the 391 CRF02_AG sequences along with all globally sampled CRF02_AG sequences (N = 3,302) as references. Phylodynamic and phylogeographic analysis was performed to the largest CRF02_AG monophyletic cluster by a Bayesian method in BEAST v1.8.0 and by reconstructing ancestral states using the criterion of parsimony in Mesquite v3.4, respectively.Results: The HIV-1 CRF02_AG prevalence differed across Spanish autonomous communities we sampled from (p &lt; 0.001). Phylogenetic analysis revealed that 52.7% of the CRF02_AG sequences formed 56 monophyletic clusters, with a range of 2–79 sequences. The CRF02_AG regional dispersal differed across Spain (p = 0.003), as suggested by monophyletic clustering. For the largest monophyletic cluster (subepidemic) (N = 79), 49.4% of the clustered sequences originated from Madrid, while most sequences (51.9%) had been obtained from men having sex with men (MSM). Molecular clock analysis suggested that the origin (tMRCA) of the CRF02_AG subepidemic was in 2002 (median estimate; 95% Highest Posterior Density-HPD interval: 1999–2004). Additionally, we found significant clustering within the CRF02_AG subepidemic according to the ethnic origin.Conclusion: CRF02_AG has been introduced as a result of multiple introductions in Spain, following regional dispersal in several cases. We showed that CRF02_AG transmissions were mostly due to regional dispersal in Spain. The hot-spot for the largest CRF02_AG regional subepidemic in Spain was in Madrid associated with MSM transmission risk group. The existence of subepidemics suggest that several spillovers occurred from Madrid to other areas. CRF02_AG sequences from Hispanics were clustered in a separate subclade suggesting no linkage between the local and Hispanic subepidemics

Evaluation of heavy metal toxicity in two Colombian agricultural soils using

La presente investigación tuvo como objetivo determinar la toxicidad de Cu, Cd, Ni, Pb y Zn, en dos suelos agrícolas colombianos, Andisol y Vertisol, mediante bioensayos con Lactuca sativa y Vibrio fischeri. Los metales se adicionaron individualmente a los suelos hasta superar el nivel de intervención de Andalucía. Posteriormente se incubaron a 25 °C y 60% de humedad, durante 60 y 90 días, respectivamente. El diseño experimental fue un completamente al azar con tres repeticiones. Luego de cada incubación se determinó la concentración de los metales en extractos acuosos, y con ellos se efectuaron bioensayos con Lactuca Sativa y Vibrio fischeri. Se efectuó análisis estadístico de resultados, comparaciones post hoc (Tukey), correlaciones y análisis de componentes principales, para encontrar los factores que afectaron los organismos en estudio. Se encontró que el Vertisol presentó mayor capacidad de inmovilización de los metales, en función de su contenido de arcillas y pH neutro, lo cual se reflejó en menor toxicidad sobre las especies en ensayo, indicando que este suelo actuó como protectante contra la movilidad de contaminantes en solución del suelo. El ensayo con V. fischeri presentó mayor sensibilidad a los contaminantes, permitiendo una mejor discriminación de los niveles de toxicidad. La capacidad de ambos suelos de inhibir la toxicidad se incrementó con el tiempo, posiblemente por interacción de los metales con los diferentes componentes de los suelos, y la disminución de su movilidad por mecanismos como la formación de complejos estables, y se relacionó con el incremento del pH

Evolución de la multirresistencia a antibióticos en aislados clínicos de Escherichia coli y Klebsiella pneumoniae procedentes de urocultivos

El aumento de la resistencia a los antibióticos dificulta la instauración de tratamientos empíricos correctos. Concretamente, el tratamiento de infecciones del tracto urinario causadas por enterobacterias multirresistentes (multi‑R, resistencia a tres o más grupos diferentes de antibióticos) es complicado debido a las escasas alternativas orales, lo que hace replantear la utilización de antibióticos en desuso, combinación de antibióticos o utilización de agentes intravenosos.Sin financiación1.530 JCR (2015) Q3, 59/83 Infectious diseases; Q4, 97/123 MicrobiologyUE